![]() ![]() The shares were sold at an average price of $322.57, for a total value of $483,855.00. Also, SVP Silji Abraham sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, March 9th. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Following the sale, the director now owns 43,616 shares in the company, valued at $15,944,701.12. The stock was sold at an average price of $365.57, for a total transaction of $443,070.84. Hofmann sold 1,212 shares of the company’s stock in a transaction dated Monday, May 1st. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Following the completion of the sale, the director now owns 43,616 shares in the company, valued at $15,944,701.12. The stock was sold at an average price of $365.57, for a total value of $443,070.84. Insider Transactions at West Pharmaceutical Services Institutional investors and hedge funds own 91.51% of the company’s stock. Finally, AustralianSuper Pty Ltd purchased a new position in shares of West Pharmaceutical Services during the fourth quarter valued at approximately $77,549,000. Two Sigma Investments LP purchased a new stake in West Pharmaceutical Services in the fourth quarter worth about $77,880,000. now owns 488,062 shares of the medical instruments supplier’s stock worth $114,866,000 after buying an additional 370,589 shares during the period. lifted its holdings in West Pharmaceutical Services by 315.5% in the fourth quarter. Bank of New York Mellon Corp now owns 1,742,487 shares of the medical instruments supplier’s stock worth $428,787,000 after purchasing an additional 502,186 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of West Pharmaceutical Services by 40.5% in the third quarter. Norges Bank bought a new position in shares of West Pharmaceutical Services in the fourth quarter valued at approximately $237,367,000. Several hedge funds have recently modified their holdings of WST. Institutional Investors Weigh In On West Pharmaceutical Services During the same quarter last year, the firm earned $2.30 EPS. 5% compared to the same quarter last year. West Pharmaceutical Services had a net margin of 19.15% and a return on equity of 24.14%. The company had revenue of $716.60 million for the quarter, compared to analyst estimates of $697.28 million. The medical instruments supplier reported $1.98 EPS for the quarter, beating the consensus estimate of $1.67 by $0.31. West Pharmaceutical Services ( NYSE:WST – Get Rating) last released its earnings results on Thursday, April 27th. The stock has a market cap of $26.73 billion, a price-to-earnings ratio of 49.45, a P/E/G ratio of 7.59 and a beta of 1.09. The company has a current ratio of 3.62, a quick ratio of 2.79 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services has a 12 month low of $206.19 and a 12 month high of $376.72. The company has a 50-day moving average price of $348.00 and a 200-day moving average price of $286.19. West Pharmaceutical Services Trading Down 0.0 % Based on data from, West Pharmaceutical Services currently has an average rating of “Hold” and an average target price of $313.00. ![]() Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Finally, assumed coverage on West Pharmaceutical Services in a report on Thursday, March 16th. Deutsche Bank Aktiengesellschaft raised their price objective on West Pharmaceutical Services from $250.00 to $290.00 in a report on Wednesday, February 22nd. Stephens raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $330.00 to $400.00 in a research note on Tuesday, April 11th. Ke圜orp raised their price objective on shares of West Pharmaceutical Services from $315.00 to $375.00 and gave the stock an “overweight” rating in a report on Friday, February 17th. A number of other research firms also recently issued reports on WST.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |